Morquio A Syndrome

Morquio A Syndrome

Overview

Morquio A syndrome (MPS IVA) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme N-acetylgalactosamine-6-sulfatase (GALNS), leading to accumulation of the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate[@intrathecal]. This disorder is characterized by progressive multisystem involvement, most prominently affecting the skeletal system (short stature, skeletal dysplasia, cervical spine instability), sensory organs (corneal clouding, hearing loss), and respiratory and cardiovascular systems. Unlike some other mucopolysaccharidoses, Morquio A typically does not cause significant intellectual disability.

Genetics

Gene Defect

Morquio A is caused by pathogenic variants in the GALNS gene (chromosome 16q24.3), which encodes the enzyme N-acetylgalactosamine-6-sulfatase[@intrathecal]. This enzyme is a sulfatase that removes the 6-sulfate group from N-acetylgalactosamine-6-sulfate residues in keratan sulfate and chondroitin-6-sulfate.

Inheritance Pattern

• Autosomal recessive inheritance
• Both copies of GALNS must be defective
• Parents are carriers (heterozygotes)
• Each pregnancy has 25% chance of affected child

Common Variants

Over 200 pathogenic variants have been identified:

• p.G301C — Common in Caucasian populations
• p.R94C — Frequent missense variant
• p.W333X — Nonsense variant
• Various missense, nonsense, splice site, deletion, and insertion variants
• Genotype-phenotype correlation is limited

Epidemiology

...

Morquio A Syndrome

Overview

Morquio A syndrome (MPS IVA) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme N-acetylgalactosamine-6-sulfatase (GALNS), leading to accumulation of the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate[@intrathecal]. This disorder is characterized by progressive multisystem involvement, most prominently affecting the skeletal system (short stature, skeletal dysplasia, cervical spine instability), sensory organs (corneal clouding, hearing loss), and respiratory and cardiovascular systems. Unlike some other mucopolysaccharidoses, Morquio A typically does not cause significant intellectual disability.

Genetics

Gene Defect

Morquio A is caused by pathogenic variants in the GALNS gene (chromosome 16q24.3), which encodes the enzyme N-acetylgalactosamine-6-sulfatase[@intrathecal]. This enzyme is a sulfatase that removes the 6-sulfate group from N-acetylgalactosamine-6-sulfate residues in keratan sulfate and chondroitin-6-sulfate.

Inheritance Pattern

• Autosomal recessive inheritance
• Both copies of GALNS must be defective
• Parents are carriers (heterozygotes)
• Each pregnancy has 25% chance of affected child

Common Variants

Over 200 pathogenic variants have been identified:

• p.G301C — Common in Caucasian populations
• p.R94C — Frequent missense variant
• p.W333X — Nonsense variant
• Various missense, nonsense, splice site, deletion, and insertion variants
• Genotype-phenotype correlation is limited

Epidemiology

• Estimated prevalence: 1 in 200,000 to 1 in 300,000 births
• Higher incidence in certain populations due to founder effects
• No ethnic predominance

Pathophysiology

Enzyme Function

N-acetylgalactosamine-6-sulfatase (GALNS) is a lysosomal hydrolase that catalyzes the desulfation of[@intrathecal]:

• Keratan sulfate — Main substrate in cornea and cartilage
• Chondroitin-6-sulfate — Component of cartilage and connective tissue

Accumulated Substrates

• Keratan sulfate — Accumulates in cornea, cartilage, bone
• Chroitin-6-sulfate — Particularly in cartilage

Pathogenesis

The accumulation of GAGs leads to[@intrathecal][@clinical]:

• Cellular dysfunction — Lysosomal swelling and cytoplasmic vacuolization
• Extracellular matrix disruption — Tissue architecture disruption
• Cellular signaling alterations — Growth factor and cytokine dysregulation
• Chronic inflammation — Tissue damage triggers inflammatory responses

Tissue-Specific Effects

• Cartilage — Proteoglycan accumulation disrupts growth and structure
• Bone — Endochondral ossification abnormalities cause skeletal dysplasia
• Cornea — GAG deposition causes clouding
• Hearing — Middle ear and inner ear involvement
• Heart valves — Deposition causes thickening and dysfunction
• Airways — GAG accumulation narrows passages

Clinical Features

Onset and Progression

• Symptoms typically appear in early childhood (1-3 years)
• Progressive deterioration throughout life
• Variable rate of progression
• Survival into adulthood common with modern management

Skeletal System

The hallmark of Morquio A is severe skeletal dysplasia[@clinical]:

• Short stature — Final adult height typically 120-140 cm
• Dysostosis multiplex — Characteristic skeletal pattern:
• Short trunk with disproportionately short limbs
• Pectus carinatum (prominent chest)
• Kyphoscoliosis
• Lumbar hyperlordosis
• Genu valgum (knock knees)
• Pes planus (flat feet)
• Widened metaphyses
• Cervical spine instability — Atlantoaxial subluxation (most critical complication)
• Risk of spinal cord compression
• Requires surgical stabilization in many patients
• Can cause quadriplegia or death if untreated
• Odontoid dysplasia — Abnormal odontoid process
• Hip dysplasia — Coxa valga, acetabular dysplasia

Sensory Organs

• Corneal clouding — Progressive, may require corneal transplantation
• Hearing loss — Mixed sensorineural and conductive
• Retinal degeneration — Less common than in other MPS disorders

Respiratory System

• Upper airway obstruction — Thickened vocal cords, narrowed trachea
• Sleep-disordered breathing — Obstructive sleep apnea common
• Restrictive lung disease — Reduced lung capacity from skeletal deformity
• Recurrent respiratory infections — Due to aspiration and impaired clearance

Cardiovascular System

• Valvular disease — Mitral and aortic valve thickening/stenosis
• Coronary artery disease — Accelerated atherosclerosis
• Cardiomyopathy — Less common

Other Features

• Dental abnormalities — Widely spaced teeth, thin enamel
• Inguinal/umbilical hernias — Common
• Joint hypermobility — Paradoxically present with stiffness
• Carpal tunnel syndrome — Median nerve compression

Intelligence

• Intelligence typically normal
• Learning difficulties may occur secondary to sensory deficits
• Some patients have normal IQ

Diagnosis

Clinical Suspicion

Diagnosis should be suspected in children with:

• Progressive short stature with normal birth length
• Characteristic skeletal dysplasia
• Corneal clouding
• Hearing loss
• Normal intelligence

Biochemical Testing

• Enzyme assay — Reduced GALNS activity in leukocytes or fibroblasts
• Urinary GAGs — Elevated keratan sulfate (quantitative and qualitative)
• Blood spot testing — Newborn screening in some regions

Genetic Testing

• GALNS gene sequencing — Identifies pathogenic variants
• Deletion/duplication analysis — Detects larger variants
• Carrier testing — Available for family members
• Prenatal diagnosis — Possible with known family variants

Imaging

• Skeletal survey — Documents dysostosis multiplex
• Cervical spine MRI/CT — Assesses atlantoaxial instability
• Echocardiography — Evaluates cardiac involvement
• Sleep study — Assesses sleep-disordered breathing

Differential Diagnosis

• Other mucopolysaccharidoses (MPS I, II, IVB, VI, VII)
• Other skeletal dysplasias
• Spondyloepiphyseal dysplasia
• Kniest dysplasia

Treatment

Enzyme Replacement Therapy

Elosulfase alfa (Vimizim) is the first and only approved enzyme replacement therapy for Morquio A[@clinical]:

• Recombinant human GALNS
• Weekly intravenous infusion
• Improves endurance and walking ability
• Reduces urinary keratan sulfate
• Approved in US (2014), Europe (2014), and other regions

Supportive Care

Multidisciplinary management is essential[@clinical]:

Orthopedic Management:

• Cervical spine stabilization surgery (posterior C1-C2 fusion)
• Scoliosis management
• Hip reconstruction
• Knee realignment
• Physical therapy

Ophthalmologic Care:

• Regular ophthalmologic exams
• Corneal transplantation if needed
• Low vision aids

Audiologic Care:

• Hearing aids for hearing loss
• Ventilation tubes for otitis media

Respiratory Care:

• Sleep studies
• CPAP/BiPAP for sleep apnea
• Respiratory therapy
• Vigilance for respiratory infections

Cardiac Care:

• Regular echocardiography
• Valve replacement if severe

Dental Care:

• Regular dental care
• Anesthesia considerations for skeletal abnormalities

Experimental Therapies

• Gene therapy — AAV vectors in clinical trials
• Substrate reduction therapy — Under investigation
• Chaperone therapy — Pharmacological chaperones in development
• mRNA therapy — mRNA-based protein delivery

Prognosis

Life Expectancy

• With modern multidisciplinary care, many patients survive into adulthood
• Mortality often related to respiratory complications or cervical spine instability
• Early diagnosis and intervention improve outcomes

Quality of Life

• Significant physical disability from skeletal abnormalities
• Mobility often requires aids (walkers, wheelchairs)
• Sensory deficits impact daily life
• Social and psychological support important

Disease Progression

• Progressive throughout life
• Skeletal disease tends to stabilize in adulthood
• Respiratory and cardiac disease may progress
• Life expectancy improved with modern treatment

Research Directions

Biomarkers

• Urinary keratan sulfate — Disease monitoring
• Serum KS — Therapeutic response
• Functional assessments — 6-minute walk test, endurance measures

New Therapies

• Next-generation ERT with better CNS penetration
• Gene therapy trials
• Combination approaches
• Disease-modifying interventions

Outcome Measures

• Natural history studies
• Quality of life measures
• Long-term efficacy data

See Also

• [GALNS Gene](/genes/galns) — Causative gene
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders) — Disease category
• [Mucopolysaccharidoses](/diseases/mucopolysaccharidoses) — Related disorders
• [Keratan Sulfate](/mechanisms/keratan-sulfate-metabolism) — Accumulated substrate

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Intrathecal idursulfase-IT in children younger than 3 years with neuronopathic mucopolysaccharidosis II in a single-arm, open-label, phase 2/3 substudy and extension.](https://pubmed.ncbi.nlm.nih.gov/41737901/) (2026 Mar) - JIMD reports
• [Clinical expert opinion on the role of elosulfase alfa in non-ambulatory individuals with Morquio A syndrome.](https://pubmed.ncbi.nlm.nih.gov/41623319/) (2026 Mar) - Molecular genetics and metabolism reports
• [Safety profile of idursulfase administered at home in patients with mucopolysaccharidosis II enrolled in the Hunter Outcome Survey.](https://pubmed.ncbi.nlm.nih.gov/41547052/) (2026 Mar) - Molecular genetics and metabolism
• [Cervicothoracic Kyphosis and Spinal Cord Compression in Hurler Syndrome.](https://pubmed.ncbi.nlm.nih.gov/41066611/) (2026 Mar 1) - Journal of pediatric orthopedics
• [AAV Gene Therapy for MPS IVA with Induction of Immune Tolerance via Oral Administration of Epitope Peptides of N-Acetylgalactosamine-6-sulfate Sulfatase.](https://pubmed.ncbi.nlm.nih.gov/41828510/) (2026 Feb 28) - International journal of molecular sciences

References